Assertio Therapeutics Announces Sale of Gralise® for Total Transaction Value of $127.5 Million
Under the terms of the agreement,
“This transaction continues the transformation of Assertio, allows us to focus on our growth products, CAMBIA® and Zipsor®, strengthens our balance sheet, and increases our flexibility for future business development opportunities,” said
The Company will provide an update on the financial impact of the sale of Gralise® following the close of the transaction.
Gralise® is a prescription medicine used to treat pain after shingles, or postherpetic neuralgia (PHN).
To learn more about
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements. These statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated, including risks related to regulatory approval and clinical development of long-acting cosyntropin, expectations regarding potential business opportunities and other risks outlined in the Company's public filings with the
Investor and Media Contact:
SVP, Investor Relations and Corporate Communications
Source: Assertio Therapeutics, Inc.
Minimum 15 minutes delayed.